Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease

NCT ID: NCT00769236

Last Updated: 2014-08-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Study Completion Date

2010-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We propose to study the intestinal secretion of ASCA by evaluating them in biopsy culture supernatants from a cohort of patients suffering from CD (n=80) and a cohort of control patients (UC (n=40) and patients without IBD (n=40 )).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Its diagnosis is based upon clinical, endoscopic and histological parameters but recent studies have shown that seric evaluation of immunological markers (anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil cytoplasmic auti-antibodies (ANCA)) could be useful. Crohn's disease (CD) is an inflammatory bowel disease (IBD) of the young people. Antibodies anti-chitobisoside carbohydrate (ACCA), anti-laminaribioside carbohydrate (ALCA) and anti-mannobioside carbohydrate (AMCA) have been described as new serological markers of CD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients with crohn disease

Group Type OTHER

Blood sampling and biopsy

Intervention Type OTHER

Biopsy and blood : Research for various antibodies

2

Patients reached by hemorrhagic first side-colitis

Group Type OTHER

Biopsy and blood sampling

Intervention Type OTHER

Biopsy and blood : research for various antibodies

3

Patients controls

Group Type OTHER

Biopsy and blood sampling

Intervention Type OTHER

Blood and biopsy : research for various antibodies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sampling and biopsy

Biopsy and blood : Research for various antibodies

Intervention Type OTHER

Biopsy and blood sampling

Biopsy and blood : research for various antibodies

Intervention Type OTHER

Biopsy and blood sampling

Blood and biopsy : research for various antibodies

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients reached by disease of crohn
* patients reached by hemorrhagic first side-colitis

Exclusion Criteria

* Forms ileales or ano-périneales pure of disease of crohn
* indefinite colitis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sophie Desplat-Jego, MD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique des Hopitaux de Marseille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Laboratoire d'Immunologie - Hopital de la Conception

Marseille, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-05

Identifier Type: -

Identifier Source: secondary_id

2008-A00080-55

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.